On Thursday, Shares of Apple Inc. (NASDAQ:AAPL), lost -2.04% to $120.07.
Apple Inc. dropped down for a fifth day, posting its first successive 2 percent declines since 2013 and pushing shares to the brink of a 10 percent correction. The slide comes amid a rout in China’s market that is occurring two weeks before the company reports earnings, according to Bloomberg.
Losses in Chinese equities, where almost $4 trillion has been erased in a month long deluge, may leave consumers with less money to buy gadgets. The Cupertino, California-based company releases third-quarter results on July 21, its first report to comprise sales of the Apple Watch. Bloomberg Reports.
In other news, Apple, unveiled iOS 9, giving a preview of new iPhone®, iPad® and iPod touch® software that will be accessible this fall. In this forthcoming release, iOS devices become more intelligent and proactive with powerful search and improved Siri® features — all without compromising users’ privacy. New multitasking features designed specifically for iPad allow you to work with two apps simultaneously, side-by-side or with the new Picture-in-Picture feature, to keep watching a video while browsing the web, composing email or using any other app. Built-in apps become more powerful in iOS 9 with detailed transit information in Maps*, a redesigned Notes app with new ways to capture ideas, and an all-new News app for the best news reading experience on any mobile device.
Apple Inc. designs, manufactures, and markets mobile communication and media devices, personal computers, watches, and portable digital music players worldwide. The company also sells related software, services, accessories, networking solutions, and third-party digital content and applications.
Shares of The Walt Disney Company (NYSE:DIS), inclined 0.36% to $115.60, during its last trading session, hitting its highest level.
The Walt Disney Company, declared the 2015 class of the Disney Accelerator program powered by Techstars. The second Disney Accelerator program features ten startup companies that will take part in a three-month mentorship and investment program started recently and concluding with a Demo Day on October 6, 2015.
The companies selected for the 2015 Disney Accelerator program comprise:
- Decisive: Decisive is a Software as a Service (SaaS) platform that uses real time data to enable advertisers to optimize mobile ad creative and targeting based on user engagement.
- EMOTIV: EMOTIV is a bioinformatics company that uses electroencephalography (EEG) to track mental performance, monitor emotions, and control virtual and physical objects with thoughts.
- FEM Inc.: FEM Inc. has developed a personalized video engagement platform based on neuroscience and psychology that maps the emotional dimensions of how and why content resonates.
- HYP3R: HYP3R enables businesses and brands to identify influential customers at their locations and engage them in real time, when it matters most.
- imperson: imperson provides an artificial intelligence platform enabling fans to have conversations with their favorite movie and TV characters.
- Littlstar: Littlstar aggregates industry leading virtual reality content with its device agnostic discovery and distribution platform.
- MakieLab: MakieLab lets kids bring toys to life by building their own customizable 3D-printed toys through creative games and apps.
- Open Bionics: Open Bionics is a robotics company creating affordable 3D-printed bionic hands for amputees, researchers and makers.
- Pundit: Pundit lets creators host audio Ask Me Anything (AMA’s) with their Twitter network, transforming the talk radio experience for the social media age.
- StatMuse: StatMuse is developing an artificial intelligence platform to assist sports fans explore data using simple, natural language.
The Walt Disney Company, together with its auxiliaries, operates as an entertainment company worldwide. The company operates in five segments: Media Networks, Parks and Resorts, Studio Entertainment, Consumer Products, and Interactive.
Finally, Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), ended its last trade with -10.43% loss, and closed at $7.47.
Anthera Pharmaceuticals, declared the pricing of an underwritten public offering of 3,333,334 shares of its common stock, offered at a price of $7.50 per share. The Company estimates that the gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Anthera, will be about $25 million. The offering is predictable to close on or about July 14, 2015, subject to customary closing conditions. In addition, Anthera has granted the underwriters a 30-day option to purchase up to an additional 500,000 shares of common stock. The Company intends to use the net proceeds from the offering for clinical research and development and general corporate purposes.
Citigroup Global Markets Inc. and Piper Jaffray & Co. are acting as joint book-running managers for the offering. SunTrust Robinson Humphrey, Inc. is acting as co-manager.
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for patients with unmet medical needs. It is developing blisibimod, a Phase III product candidate that targets B-cell activating factor associated with various B-cell mediated autoimmune diseases, counting systemic lupus erythematosus, Immunoglobulin A nephropathy, lupus nephritis, and others.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
